natgillin/translations-raw huggingface dataset:
An IL-17 binding antibody or active fragment thereof comprising both heavy (VH) and light chain (VL) variable domains, wherein said IL-17 binding antibody or active fragment thereof are capable of inhibiting the activity of 1 nM human IL-17 at a concentration of less than 5 nM by 50%, said inhibitory activity being measured on IL-6 production induced by hu-IL-17 in human dermal fibroblasts. 
IL-17-vezivno protutijelo ili njegov fragment, naznačeno time, da obuhvaća varijabilne domene kako teškog lanca (VH) tako i lakog lanca (VL), za uporabu u liječenju upalnog artritisa, pri čemu spomenuto IL-17-vezivno protutijelo ili njegov fragment sadrži najmanje jedno mjesto za vezanje antigena, koje obuhvaća sljedeće:
A yellow solid was obtained which was used in the next step without any further purification. 
Dobivena je žuta krutina koja se koristi u slijedećem koraku bez daljnjeg pročišćavanja.
Use of claim 10, wherein the disorder or the disease is selected from hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia. 
Uporaba prema zahtjevu 10, naznačen time, da poremećaj ili bolest je odabran/a od sljedećih: hiperlipidemija, arterioskleroza, = ateroskleroza, = periferna = vaskularna = bolest, = dislipidemija, = hiperbetalipoproteinemija, hipoalfalipoprotemnemija, = hiperkolesterolemija, = hipertrigliceridemija, = familijarna - hiperkolesterolemija, HR P20140183 T1 kardiovaskularni poremećaj, koronarna srčana bolest, koronarna arterijska bolest, koronarna vaskularna bolest, angina, ishemija, srčana ishemija, tromboza, kardijski infarkt kao što je miokardijski infarkt, srčani udar, periferna vaskularna bolest, reperfuzijska ozljeda, angioplastična restenoza, hipertenzija, kongestivni srčani zastoj, dijabetes kao što je dijabetes mellitus tipa II, dijabetske vaskularne komplikacije, pretilost ili endotoksinemija.
More preferred embodiments of the invention are capable of delivering 1.5 mg or more of aerosol in the first 3 puffs. 
Poželjnije realizacije iz izuma mogu da provedu 1.5 mg ili više aerosola u prva 3 dima.
This invention relates to certan dihydropyridines, specifically to certain 1,4-dihydropyridines having a basic amino-containing group attached to the 2-position, which have utility as anti-ischaemic and antihypertensive agents. 
Tehnički problem Izum se odnosi na postupak za dobivanje izvjesnih 1,4-dihidropiridina koji imaju baznu grupu koja sadrži amino grupu u 2-položaju i koji su korisni kao anti-iskemična i antihipertenzijska sredstva,
A compound according to any one of claims 1 to 20, 22, 24, 26 or 28, or a pharmaceutically acceptable salt thereof, for use in the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS. 
Kombinacija prema bilo kojem od patentnih zahtjeva 1-4, za uporabu u profilaksi infekcije HIV-om ili profilaksi SIDA-e kod subjekta. Kombinacija prema bilo kojem od patentnih zahtjeva 1-4, za uporabu u liječenju infekcije HIV-om, liječenju SIDA-e, ili odlaganju početka SIDA-e kod subjekta.
Ar is selected from the group consisting of phenyl and thiophen-yl; is selected from the group consisting of unsubstituted imidazolyl and substituted imidazolyl, wherein the substituted imidazolyl group is substituted with C1-C6 alkyl; is selected from the group consisting of hydrogen, methyl, chloro, fluoro, hydroxy, methoxy, ethoxy, propoxy, carbamoyl, dimethylamino, amino, formamido, and trifluoromethyl; and 
Spoj za uporabu prema zahtjevu 23, ili njegova farmaceutski prihvatljiva sol, naznačen,a time, da Ar je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani piridinil, tiazolil i supstituirani tiazolil. Spoj za uporabu prema zahtjevu 23, ili njegova farmaceutski prihvatljiva sol, naznačen,a time, da Ar je odabran iz skupine - koju = čine:
A pharmaceutical composition according to claim 12, wherein R3 is thienyl. 
Farmaceutska kompozicija prema patentnom zahtjevu 12, naznačena time što je R; jednako tienil.
R1h and R1i each independently mean a hydrogen atom, or mean a C1-C6 alkyl, C2-C7 alkanoyl or C1-C6 alkylsulfonyl group optionally having a substituent selected from a group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkoxy group, a C3-C6 cycloalkyl group, a C2-C7 alkanoyl group and a C1-C6 alkylsulfonyl group; and X means a group of =NH or =O], or a pharmaceutically acceptable salt or N-oxide derivative thereof. 
h i R1i svaki nezavisno predstavlja atom vodika, ili predstavlja C1-C6 alkil, C2-C7 alkanoil ili C1-C6 alkilsulfonil grupu koja opcionalno ima supstituend odabran iz grupe koja se sastoji od atoma halogena, hidroksilne grupe, cijano grupe, C1-C6 alkoksi grupe, C3-C6 cikloalkil grupe, C2-C7 alkanoil grupe i C1-C6 alkilsulfonil grupe; i X predstavlja =NH, ili farmaceutski prihvatljivu sol ili njen N-oksid derivat.
The multiparticulate subunits (X) and (Y) of identical shape should also not be visually distinguishable from one another so that the abuser cannot separate them from one another by simple sorting. 
Dotične multipartikularne podjedinice (X), odnosno (Y) s identičnim oblikovanjem također se ne bi trebale vizualno razlikovati jedna od druge, da ih zlorabitelj ne bi mogao jednostavnim sortiranjem odijeliti jednu od druge.
for use in a method of treating, preventing, diagnosing or monitoring a cancer disease characterized by expression of the protein or polypeptide. 
Farmaceutski pripravak radi primjene sukladno bilo kojem od zahtjeva 1 do 5, što je u obliku cjepiva.
A method for automatically picking up articles (A), comprising: 
Metoda za automatsko preuzimanje artikala (A) koja obuhvaća:
R6a is hydrogen, or lower alkyl optionally substituted by substituent group C, and 
RS je vodik, ili niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i
CHO) cultured host cells transfected with vectors encoding such proteins or in transgenic animals or plants. 
CHO) stanicama transfektiranim sa vektorima koji kodiraju za takve proteine, ili u transgenim životinjama, ili biljkama.
A process for preparing cortexolone-17a-propionate in crystalline form I, comprising: reacting a compound of Formula IIa: wherein R is CH3CH2, with a compound of Formula III R'OH (III) wherein R' is a linear aliphatic chain containing 1-10 carbon atoms, in the presence of a lipase from Candida, and crystallizing the cortexolone-17a-propionate of crystalline form I from tert-butylmethylether solvent. 
R'OH (II) u prisutnosti lipaze iz kvasca Candida, gdje je R CH3-CH., a R' je nerazgranati alifatski lanac s 1-10 atoma ugljika, kako bi se dobilo korteksolon-17a-propionat, te u kristaliziranju navedenog korteksolon-174-propionata iz terc- butil-metil-etera kako bi se dobilo korteksolon-17a-propionat u kristalnom obliku I.
and ethyl alcohol to form an adduct of the quinine and Compound (C-1) 
s kininom i etil-alkoholom kako bi se dobilo adukt kinina sa Spojem (C-1):
optionally substituted heteroaryl; or R10a and R10b taken together with the carbon atom to which they are attached form a 3- to 8-membered optionally substituted cycloalkyl or a 3- to 8-membered optionally substituted heterocyclo; 
R'*i R'" uzeti zajedno s atomom ugljika za koji su pričvršćeni tvore 3- do 8- člani opcionalno supstituirani cikloalkil ili 3- do 8- člani opcionalno supstituirani heterocikl; rje 1,2,1li 3; sje 1,2, ili 3;
R21A and R24A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted -O-C1-24 alkyl and an optionally substituted -O-aryl; 
A i R24A su neovisno odabrani iz skupine koja sadrži vodik, po izboru supstituiran C1-24 alkil, po izboru supstituiran aril, po izboru supstituiran -O-C1-24 alkil i po izboru supstituiran -O-aril;
contacting the boron “ate” complex of formula (II) with a Lewis acid under conditions that afford the boronic ester compound of formula (I): 
(b) dovođenje u kontakt kompleksa borata formule (II) sa Lewis-ovom kiselinom pod uvjetima koji daju ester organoborne kiseline formule (2):
The solid oral extended release pharmaceutical dosage form of anyone of claims 1 to 8, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3, preferably equal to or less than about 1.19 g/cm3. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 13, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/cm3, poželjno jednaka ili manja od oko 1.19 g/cm3.
A method for magnetically transferring predeterminable indicia onto a printed document, comprising the steps of applying a layer of an ink or a coating composition to at least a part of a first surface of a sheet or web, said ink or coating composition comprising at least one type of magnetic or magnetizable particles; exposing the sheet or web of step a), while the ink or coating composition is wet, to a magnetic field at a surface of a body of permanent-magnetic material, said body of permanent-magnetic material being either a flat plate, or a cylindrically curved plate, and said surface of said body of permanent-magnetic material is carrying predeterminable indicia in form of engravings, thereby allowing the said magnetic or magnetizable particles to orient in the said magnetic field; and 
Postupak za magnetsko prenošenje unaprijed određene oznake, poput uzorka ili slike, na otisnuti dokument, koji obuhvaća sljedeće korake: a) nanošenje sloja tinte ili smjese za premazivanje na najmanje jedan dio gornje površine lista ili tkanine, a navedena tinta ili smjesa za premazivanje sadrže najmanje jednu vrstu magnetskih čestica ili čestica koje se mogu magnetizirati; b) izlaganje premazanog lista ili tkanine iz koraka a), za vrijeme dok je nanesena tinta ili smjesa za premazivanje još uvijek vlažna, djelovanju magnetskog polja na površini tijela od permanentno magnetskog materijala, pri čemu je navedeno tijelo ravna ploča ili cilindrična zakrivljena ploča, poželjno postavljena na rotirajući cilindar na tiskarskom stroju, a navedena površina navedenog tijela ima unaprijed određene oznake u obliku gravura, čime se omogućuje usmjeravanje navedenih magnetskih čestica ili čestica koje se mogu magnetizirati u navedenom magnetskom polju;
The volume element is particularly advantageously usable as a water sports equipment, in particular as a surfboard, floating island, airbed or the like. 
Element za napuhavanje (10) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što element za napuhavanje (10) je načinjen kao oprema za sportove na vodi, osobito kao daska za surfanje, ploveći otok, zračni krevet i slično.
The polymorph of claim 4 obtained by crystallizing the tosylate salt of Compound 1: from isopropanol. 
Polimorf u skladu s patentnim zahtjevom 2, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1: [image] iz izopropanola.
In still another embodiment of the present disclosure, the aqueous alcohol is selected from a group comprising ethanol, methanol, n-propanol, 2-propanol, glycerol, PEG, PPG, ethylene glycol and propylene glycol. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što navedeni vodeni alkohol se bira iz skupine koju čine etanol, metanol, n-propanol, 2-propanol, glicerol, PEG, PPG, etilen-glikol i propilen-glikol.
A process according to claim 1, wherein the process is sequential, and step (iii) takes place immediately after step (ii). 
Postupak u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je postupak sekvencijalan, a korak (111) se odvija odmah nakon koraka (ii).
Step 2: Synthesis of compound (c) 
Korak 2 Sinteza spoja (c)
A polynucleotide encoding an antibody of any of the preceding paras. 
Polinukleotid koji kodira protutijelo iz bilo kojeg od prethodnih patentnih zahtjeva.
contacting the antigen presenting cells of step (iii) with T-cells to evaluate the ability of the peptide to stimulate the T-cells; and 
(iv) stavljanja u kontakt stanice za predočavanje antigena iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da simulira T-stanicu; 1
Nanoparticles or nanoparticles' aggregates for use for altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Nanočestice HfO, ili agregati nanočestica za uporabu pri mijenjanju ili uništavanju ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO, ili gustoća spomenutih agregata nanočestica HfO, barem 7 g/em?, i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između PH 6,5 1 7,5 u fiziološkoj tekućini.
The method as in embodiment 1, wherein the pre-determined pattern (BP) is a raster pattern such that the bonded wear resistant particles are arranged with pre-determined distances (D1, D2) between each other. 
Postupak prema zahtjevu 1, naznačen time što je unaprijed određeni uzorak (BP) rasterski uzorak tako da su vezane čestice otporne na habanje raspoređene na međusobno unaprijed određenim udaljenostima (D1, D2).
The triflate (AS) can be reacted with a suitable stannane reagent in the presence of a base such as lithium chloride and a catalyst such as tetrakis triphenyl phosphine palladium (0) in a suitable solvent such as THF or toluene. 
(AVI Triftalat (AS) može reagirati s prikladnim kositrenim reagensom u prisutnosti baze poput litij klorida i katalizatora poput tetrakis trifenil fosfin paladija (0) u prikladnom otapalu poput THF ili toluena.
An isolated anti-Notch1 negative regulatory region (NRR) antibody, wherein said antibody, when bound to said Notch1 NRR, decreases Notch1 signaling, and wherein said Notch1 NRR is a human Notch1 NRR having the amino acid sequence shown as amino acids 1446 to 1735 of SEQ ID NO:56 or a mouse Notch1 NRR having the amino acid sequence shown as amino acids 1446 to 1725 of SEQ ID NO:57. 
Izolirano anti-Notch1-protutijelo negativnog regulatorskog područja (NRR), naznačeno time, da spomenuto protutijelo, kada je vezano na spomenuti Notch1-NRR, smanjuje signalizaciju od Notch1, s time da Notch1-NRR je humani Notch1-NRR koji ima amino kiselinsku sekvencu prikazanu kao amino kiseline 1446 do 1735 od SEQ ID NO:56 ili je mišji Notch1-NRR koji ima amino kiselinsku sekvencu prikazanu kao amino kiseline 1446 do 1725 od SEQ ID NO:57.
biogenic amine neurotransmitter [serotonin (5-HT), norepinephrine (NE) and dopamine (DA)] transporter reuptake blockers, and 
- - blokeri transporta re-apsorpcije biogenskih neurotransmittera amina [serotonin (5-HT), norepinefrin (NE) i dopamin (DA) transporter ponovnih blokera; i
The use according to claim 1-4, wherein the animal is a human being and the compound is in the medicament at a concentration sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGFB. 
Pripravak za uporabu prema zahtjevu 1, ili uporaba prema zahtjevu 2, ili spoj za uporabu prema zahtjevu 3, naznačen time da se spoj primjenjuje u koncentraciji koja je dovoljna za stimuliranje ekspresije citokina 1L-4,1L-10, IL-11, W-13 ili TGF B.
The operation of the invention is as follows. 
Način rada ovog izuma je sljedeći.
The antibiotic macrolide of claim 1 wherein R1 is the following group: 
Spoj u skladu s patentnim zahtjevom 1, gdje R1 je sljedeća skupina:
iii) said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or pharmaceutically acceptable salt thereof are administered as two 8 mg tablets of sustained-release naltrexone twice daily and two 90 mg tablets of sustained-release bupropion twice daily. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju kao dvije tablete od 8 mg naltreksona s usporenim oslobađanjem dva puta dnevno i dvije tablete od 90 mg bupropiona s usporenim oslobađanjem dva puta dnevno.
The starting materials for the process (the “sulfide compounds”) are tripeptides and tetrapeptides, optionally mono- or di-esterified, optionally protected at the glutamyl amine, and with the cysteine sulfur alkylated with a Z—CH2— group. 
Početni materijali za postupak (Â«sulfidni spoj Â«) su tripeptidi, po izboru mono- ili di- esterificirani, po izboru zaštićeni na glutamil aminu, i sa cistein sulfurom alkilirani sa Z-CH,- skupinom.
Additionally, the compounds of formula (I), especially 2-acetylthioisosorbide 5-mononitrate (12), their tautomers, pharmaceutically acceptable salts and solvates thereof, may also be used in a therapy for the prevention and/or treatment of atherosclerosis, cardiac allograft vasculopathy, platelet activation, thrombosis, stroke, pathological conditions where oxidative stress plays an important role in their pathogenesis, and/or tissue damage due to ischemia and/or due to ischemia-reperfusion. 
K tome, spojevi formule (I), posebno 2-acetiltio-izosorbid 5-mononitrat (12), njegovi tautomeri, farmaceutski prihvatljive soli i njegovi solvati mogu se također upotrijebiti u terapiju za prevenciju i/ili liječenje ateroskleroze, kardijalne vaskulopatije alografta, aktivacije trombocita, tromboze, udara kapi, patoloških stanja u čijoj patogenezi ima važnu ulogu oksidativan stres i/ili ozljeda tkiva zbog ishemije i/ili zbog ishemije-reperfuzije.
In more embodiments, pharmaceutical compositions are provided. Some such compositions can include an aqueous solution consisting essentially of from 80 mg/ml to 120 mg/ml levofloxacin or ofloxacin and from 160 mM to 220 mM of a divalent or trivalent cation, wherein the solution has a pH from 5 to 7 and an osmolality from 300 mOsmol/kg to 500 mOsmol/kg. 
Aerosol vodene otopine, otopina koja od 80 mg/ml do 120 mg/ml levofloksacina ili ofloksacina i od 160 mM do 220 mM dvovalentnog ili trovalentnog kationa, pri čemu otopina ima pH od 5 do 7 1 osmolalnost od 300 mOsmol/kg do 500 mOsmol/kg, za uporabu u liječenju plućne infekcije kod čovjeka, pri čemu se levofloksacin ili ofloksacin daju u dozi od 20 do 300 mg dvaput dnevno.
The individual titres for the ST1P01/r-hIL-18BP obtained in each independent experiment together with the Standard deviation, the Coefficient of Variation (%) and the 95% Confidence Limits are reported below. 
Pojedinačni titri za STIPO1/r-hIL-18BP dobiveni za svaki neovisni eksperiment skupa s Standardnom devijacijom, Koeficijentom Varijacije (%) te 95% Vjerojatnosti, prikazani su ispod.
(c8) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 33 (L406-k); (c9) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 34 (L408-k); and 
(c8) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 33; (c9) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 34; 1 (c10) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 171.
In one embodiment, provided herein are compounds of the formula (II): 
HR P20120447 T1 PATENTNI ZAHTJEVI 1. Spoj formule (II):
The final product obtained by the process of the invention is a porous matrix mainly of magnesium-hydroxyapatite or magnesium-carbonate-hydroxyapatite with a quantity of Mg2+ ions in the range of 0.2% to 1.5% by weight with respect to the matrix weight; preferably, from 0.3% to 1.0% by weight; and more preferably, from 0.4% to 0.7% by weight. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je krajnji proizvod porozni matriks uglavnom od magnezijeva hidroksiapatita ili magnezijeva karbonat-hidroksiapatita, sa količinom Mg* iona u opsegu od 0.2 do 1.5 tež. %, poželjno od 0.3 do 1.0 tež. %, poželjnije od 0.4 do 0.7 tež. %, u odnosu na težinu matriksa.
A compound of formula (1) 
S Spoj formule (1)
A compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, for use in treating a viral disease in a subject, wherein the viral disease is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia, feline leukemia virus and feline immunodeficiency virus. 
Spoj prema bilo kojem zahtjevu od 1 do 7 ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju virusnog oboljenja kod ispitanika, naznačen time, što je virusno oboljenje odabrano iz skupine koja se sastoji od ljudskog papilomavorusa, HIV-a, virusa hepatitisa B, virusa hepatitisa C, virusa boginja, virusa kravljih boginja, HR P20181871 T1 adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije, virusa mačje leukemije i virusa mačje imunodeficijencije.
The process of claim 9, wherein it is used for the enzymatic epimerization of 3a,7a,12a-trihydroxy-5B-cholanic acid (cholanic acid) of formula either 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se koristi za enzimsku epimerizaciju 3a,7a,12a-trihidroksi-5B-kolanske kiseline (količna kiselina) formule bilo
a layer 14 for protecting the inner surface of the bed 11, 
- sloj (14) za zaštitu unutarnje površine ležaja (11),
In another embodiment, the present invention provides for an injectable oil-in-water (O/W) emulsion comprising: 
Sastav cjepiva koji sadrži emulziju s uljem u vodi (O/W) za injekciju, naznačen time, da obuhvaća sljedeće:
a microwave-transparent window (54) for transmission of microwave radiation from the microwave generator (56) into the vacuum chamber (22); 
(c) mikrovalno-transparentni prozor (54) za prijenos mikrovalnog zračenja od mikrovalnog generatora (56) u vakuumsku komoru (22);
A compound having Formula II: or a pharmaceutically acceptable salt thereof, wherein: 
NIH Ra iH ili njena farmaceutski prihvatljiva sol, pri čemu:
N-butyl-2-cyanoacrylate balance. A method for producing the medical glue of claim 1 comprising mixing the glue components wherein the required quantity of 3-methacryloxysulpholane is mixed with a mixture of the required quantities of cooled N-butyl-2-cyanoacrylate and the required quantity of organic acid as stabilizer and stirred and wherein the inner surface of the container for 3-methacryloxysulpholane is preliminarily treated with sulfur dioxide as stabilizer. 
Postupak za proizvodnju medicinskog ljepila temeljem zahtjeva 1, naznačen time da se sastojci ljepila miješaju pri čemu je tražena količina 3-metakriloksisulfolana pomiješana sa smjesom tražene količine ohlađenog N-butil-2- cijanoakrilata i tražene količine organske kiseline kao stabilizatorom te promiješane, a pri čemu se unutrašnja površina spremnika 3-metakriloksisulfolana preliminarno tretira sumpornim dioksidom kao stabilizatorom.
This strip preferably extends from the rear portion of the fuel element to the mouth end of the tobacco charge 28. 
Ova vrpca 50 se poželjno proteže od zadnjeg djela gorivog elementa prema usnom kraju čepa 28 dunana.